Rare Disease Trials, Rarely Ready:
Why Most Fail Before They Begin
AI Webinar Explorer now available for enhanced on-demand viewing
About this webinar
Clinical trial failures in rare diseases aren’t due to bad drugs; they’re due to bad data, underpowered study designs and archaic recruitment strategies. The result? Years lost. Millions wasted. And patients are left waiting or worse, never receiving potentially lifesaving/changing therapies.
In this webinar, the featured speakers will explore why over half of rare disease randomized control trials fail before results are published and how a next-gen model of data normalization, intelligent cohorting and workflow-native activation can cut trial durations and reduce costs. This session will be beneficial for sponsors and CROs ready to ditch the spray-and-pray trial model and move toward precision-built studies that start faster, run leaner and leave no patient behind.
Register for this webinar to learn how to overcome common pitfalls in rare disease trials using a data-driven, precision-focused approach.
Who should attend
- CROs
- Biopharma companies (focus on rare disease or pediatrics)
- Clinical Operations teams
- Clinical Development teams
- Feasibility Managers
- Clinical Operations Leads
- Data Managers
- Medical Directors
- Therapeutic Area Leads
What you will learn
- Understand why over 50% of rare disease trials are discontinued or unpublished and how to prevent it
- See how using normalized clinical data can cut site activation and cohorting time by months
- Learn how a rare-disease-optimized trial model can improve enrollment rates and reduce screen failures
- Discover how plugging into workflow-native tools can win requests for proposals and save $50K+ per underperforming site avoided
Featured Speakers
Ediz Calay, PhD
Ediz is the Commercial Strategy Owner of IMO Health’s Life Sciences and Health Tech Solutions, with responsibility for identifying solution fit and scaling offerings to market.
Prior to joining IMO, he had worked with several top 20 pharma companies across RWE projects, clinical trial optimization and therapeutic development across oncology, immunology, infectious, metabolic and rare disease areas. He holds a PhD in Physiology and Biochemistry and completed his post-doctoral training in Biophysics, studying the pathophysiology of obesity and diabetes.
Partner for this event
IMO Health
IMO Health is a clinical data intelligence business improving how data is used across the healthcare landscape. Combining rich, highly nuanced medical terminology, extensive domain knowledge, and artificial intelligence (AI), we expertly structure and operationalize clinical data to generate sharper insights and inform more intelligent decision-making.
Regarding the recording: I think it would be easier with Ediz’s schedule if we could pre-record and provide it to you. But i’ll need you to let me know when you would need that by. He can make a decision off of that. I’ve cc’d Ediz so you have his email and our life science product marketing manager, Meghan Berdelle.
